Bank of New York Mellon’s Inhibikase Therapeutics IKT Stock Holding History

Bank of New York Mellon’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$615K	Buy	303,126 +89,918	+42%	+$161K	﹤0.01%	3647
2026 Q1	$358K	Buy	213,208 +75,723	+55%	+$134K	﹤0.01%	3764
2025 Q4	$282K	Sell	137,485 -1,182	-0.9%	-$1.88K	﹤0.01%	3891
2025 Q3	$225K	Buy	138,667 +6,194	+5%	+$10.7K	﹤0.01%	3971
2025 Q2	$258K	Buy	+132,473	New	+$259K	﹤0.01%	3874
2023 Q2	–	Sell	-6,501	Closed	-$25.7K	–	4425
2023 Q1	$25.7K	Hold	6,501	–	–	﹤0.01%	4282
2022 Q4	$19.5K	Sell	6,501 -51	-0.8%	-$202	﹤0.01%	4361
2022 Q3	$36K	Hold	6,552	–	–	﹤0.01%	4373
2022 Q2	$29K	Sell	6,552 -45	-0.7%	-$265	﹤0.01%	4447
2022 Q1	$59K	Hold	6,597	–	–	﹤0.01%	4498
2021 Q4	$58K	Hold	6,597	–	–	﹤0.01%	4477
2021 Q3	$75K	Buy	+6,597	New	+$89.2K	﹤0.01%	4382

Other funds holding IKT

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kennondale Capital Management Richmond, Virginia $150M AUM 46.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Bank of New York Mellon's IKT Position: Q2 2026 in Review

Bank of New York Mellon increased its Inhibikase Therapeutics (IKT) stake by 42% in Q2 2026, buying an estimated $161K and bringing the position to 303,126 shares worth $615K. The position accounts for ﹤0.01% of the portfolio, ranked #3647.

Bank of New York Mellon first reported a position in IKT in Q3 2021 and has held it in 12 quarters since. 42 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

Bank of New York Mellon held 303,126 shares of Inhibikase Therapeutics worth $615K as of Q2 2026.
Bank of New York Mellon bought 89,918 Inhibikase Therapeutics shares in Q2 2026, an estimated $161K.
Inhibikase Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3647 holding.
Bank of New York Mellon first reported a position in Inhibikase Therapeutics in Q3 2021 and has held it in 12 quarters since.
42 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.